Clinical trial NCT05849675: Pitolisant Effects on Affect and Cognition Exploratory Study (PEACE Study)
Official title: An fMRI Investigation of the Effects of Selective Histamine-3 Receptor Antagonism on Cognitive and Emotional Processing in Healthy Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anhedonia
Cognitive Function
Keywords: Drug
fMRI
pharmaco-fMRI
Cognition
Histamine
Lead sponsor: University of Oxford
Sponsor class: OTHER
First posted: 2023-05-09
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly allocated to one of two groups (pitolisant or placebo). This study uses a novel procedure known as variance minimisation (described in Sella, Raz \& Cohen Kadosh, 2021) to randomise participants allocation to the two intervention groups based on equalising baseline cognitive functioning and gender. Participants will receive a single dose of the drug (pitolisant, 36mg) or placebo, and undertake fMRI and cognitive/emotional assessment three hours after dose. The study is assessing the effect antagonising the H3 receptor on functional connectivity/cognitive ability, it is not an efficacy or safety study.
Primary purpose: OTHER

Brief summary: The goal of this study is to investigate the effects of selective histamine 3 antagonist pitolisant on brain function and cognition in healthy individuals. The main questions it aims to answer are:

1. Does pitolisant alter functional activity in brain regions linked to reward and cognitive processing during rest or cognitive task performance?
2. Does pitolisant alter cognitive ability across a range of psychological domains, including working memory, executive functioning and emotional processing?

Participants will undertake fMRI scanning in addition to a battery of tasks designed to measure cognitive and emotional processing after taking a single dose of pitolisant or placebo. Researchers will compare differences in functional activity, cognition and emotional processing across the pitolisant and placebo groups.

Detailed description: Cognitive and affective processing are underpinned by monoaminergic neurotransmission and neurosteroid systems, yet there are many aspects of these systems that remain unknown in humans. In particular, monoaminergic histamine 3 (H3) receptors are abundant in CNS regions underpinning cognitive processing (prefrontal cortex, hippocampus, and striatum), yet the role of these receptors in humans remains unclear. Evidence from animal models suggests H3R antagonism improves cognitive functioning, however these specific effects are yet to be examined in humans. Similarly, the function of sigma-1 (σ-1) receptors in the brain is not well understood in humans despite strong evidence of pro-cognitive effects in animal models.

The study will investigate the effect of pitolisant, a dual H3R antagonist and σ-1R agonist, on cognitive and affective processing, in addition to changes in functional connectivity. These effects will be measured with a battery of neuropsychological tasks (e.g., Affective Go/No-Go Task; Adaptive dual n-back task), self-rated measures of cognitive function (PDQ), and resting state fMRI and fMRI data acquisition during the verbal n-back and memory encoding tasks.

Eligibility criteria: Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the research
* Not currently taking any medications which may interfere with pitolisant, including psychoactive medications
* Not currently using antihistaminergic medication
* Aged 18-45 years
* Male or female
* Sufficiently fluent English to understand and complete cognitive tasks and questionnaires
* Body Mass Index above or below 18-30
* Right handed

Exclusion Criteria:

* Current pregnancy (as determined by urine pregnancy test taken during screening visit), planning to become pregnant or breast feeding
* Any past or current history of severe and/or serious psychiatric disorder, including but not limited to schizophrenia, psychosis, bipolar affective disorder, major depressive disorder, obsessive compulsive disorder
* Clinically significant abnormal values for urine drug screen, blood pressure measurement ( in accordance with AP20 'non-invasive blood pressure') and ECG. A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
* History of, or current medical conditions which, in the opinion of the investigator, may interfere with the safety of the participant or the scientific integrity of the study, including epilepsy/seizures, brain injury, hepatic or renal disease, acid-related gastro-intestinal problems, Central Nervous System (CNS) tumours, neurological conditions
* Current or past history of drug or alcohol dependency
* Severe lactose intolerance
* Use of recreational drugs (e.g. cannabis, cocaine, amphetamines) within past 3 months
* Participation in a study which uses the same computer tasks as those in the present study (determined by asking participants about previous studies participated in during screening) within past 3 months
* Participation in a study that involves the use of a medication within the last three months
* Smoking \> 5 cigarettes per day
* Consumption of a high amount of caffeine per day (\> 400ml caffeine) (e.g., 5 or more cups of coffee)
* Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator
* Any contraindication to MRI scanning (e.g. metal objects inside the body, pacemakers, significant claustrophobia)
* Not right handed

Primary outcomes:
measure: BOLD signal levels during resting state fMRI sequence
timeFrame: 3-6 hours after single dose of drug or placebo.
measure: BOLD signal levels during fMRI memory encoding task
timeFrame: 3-6 hours after single dose of drug or placebo.
measure: BOLD signal levels during fMRI n-back task
timeFrame: 3-6 hours after single dose of drug or placebo.
Secondary outcomes:
measure: Optimal choice selection during loss and reward conditions in Probabilistic Instrumental Learning Task (PILT)
timeFrame: 3-6 hours after single dose of drug or placebo.
measure: Number of inhibited 'no-go' responses during the affective Interference Go/No-Go Task performance
timeFrame: 3-6 hours after single dose of drug or placebo.
measure: Accuracy of target selection on the Colour Change Detection Task
timeFrame: 3-6 hours after single dose of drug or placebo.
measure: Accuracy of emotional labeling of facial expressions during the facial emotion recognition task
timeFrame: 3-6 hours after single dose of drug or placebo.
measure: Accuracy of target selection during n-back fMRI task
timeFrame: 3-6 hours after single dose of drug or placebo.
measure: Accuracy of stimuli labeling (novel or familiar) during fMRI memory encoding task
timeFrame: 3-6 hours after single dose of drug or placebo.
Other outcomes:
Locations:
city: Oxford
country: United Kingdom
facility: Department of Psychiatry, University of Oxford
Study officials:
affiliation: University of Oxford
name: Susannah E Murphy, DPhil
role: PRINCIPAL_INVESTIGATOR
References: